{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T07:18:08Z","timestamp":1772781488402,"version":"3.50.1"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuroscience Letters"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1016\/j.neulet.2017.01.041","type":"journal-article","created":{"date-parts":[[2017,1,18]],"date-time":"2017-01-18T13:33:00Z","timestamp":1484746380000},"page":"163-167","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Treatment of rats with the JAK-2 inhibitor fedratinib does not lead to experimental Wernicke\u2019s encephalopathy"],"prefix":"10.1016","volume":"642","author":[{"given":"Alan S.","family":"Hazell","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Szeifoul","family":"Afadlal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David A.","family":"Cheresh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashraf","family":"Azar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.neulet.2017.01.041_bib0005","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1001\/archneur.1981.00510060052007","article-title":"Model of Wernicke\u2019s encephalopathy","volume":"38","author":"Troncoso","year":"1981","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.neulet.2017.01.041_bib0010","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1111\/j.1471-4159.1993.tb03635.x","article-title":"Cerebral vulnerability is associated with selective increase in extracellular glutamate concentration in experimental thiamine deficiency","volume":"61","author":"Hazell","year":"1993","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neulet.2017.01.041_bib0015","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1046\/j.1471-4159.2001.00436.x","article-title":"Selective down-regulation of the astrocyte glutamate transporters GLT-1 and GLAST within the medial thalamus in experimental Wernicke's encephalopathy","volume":"78","author":"Hazell","year":"2001","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neulet.2017.01.041_bib0020","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/glia.20908","article-title":"Loss of astrocytic glutamate transporters in Wernicke encephalopathy","volume":"58","author":"Hazell","year":"2010","journal-title":"Glia"},{"key":"10.1016\/j.neulet.2017.01.041_bib0025","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1111\/j.1471-4159.1993.tb07457.x","article-title":"Extracellular glutamate is increased in thalamus during thiamine deficiency-induced lesions and is blocked by MK-801","volume":"61","author":"Langlais","year":"1993","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neulet.2017.01.041_bib0030","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1097\/00005072-198405000-00006","article-title":"Low energy levels in thiamine-deficient encephalopathy","volume":"43","author":"Aikawa","year":"1984","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.neulet.2017.01.041_bib0035","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.neuint.2010.11.019","article-title":"Modeling neurodegenerative disease pathophysiology in thiamine deficiency: consequences of impaired oxidative metabolism","volume":"58","author":"Jhala","year":"2011","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.neulet.2017.01.041_bib0040","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1186\/s12967-015-0644-4","article-title":"Effect of treatment with a JAK2-selective inhibitor, fedratinib, on bone marrow fibrosis in patients with myelofibrosis","volume":"13","author":"Jamieson","year":"2015","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.neulet.2017.01.041_bib0045","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1200\/JCO.2010.32.8021","article-title":"Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis","volume":"29","author":"Pardanani","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.neulet.2017.01.041_bib0050","doi-asserted-by":"crossref","first-page":"e335","DOI":"10.1038\/bcj.2015.63","article-title":"A phase 2 randomized dose-ranging study of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosis","volume":"5","author":"Pardanani","year":"2015","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.neulet.2017.01.041_bib0055","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1002\/ajh.23703","article-title":"Primary myelofibrosis: 2014 update on diagnosis, risk-stratification, and management","volume":"89","author":"Tefferi","year":"2014","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.neulet.2017.01.041_bib0060","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1001\/jamaoncol.2015.1590","article-title":"Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis: a randomized clinical trial","volume":"1","author":"Pardanani","year":"2015","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.neulet.2017.01.041_bib0065","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1093\/ajcp\/55.4.465","article-title":"Analysis of blood transketolase activity","volume":"55","author":"Massod","year":"1971","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.neulet.2017.01.041_bib0070","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1046\/j.1471-4159.1997.68052216.x","article-title":"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) decreases glutamate uptake in cultured astrocytes","volume":"68","author":"Hazell","year":"1997","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neulet.2017.01.041_bib0075","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/glia.10241","article-title":"Thiamine deficiency results in downregulation of the GLAST glutamate transporter in cultured astrocytes","volume":"43","author":"Hazell","year":"2003","journal-title":"Glia"},{"key":"10.1016\/j.neulet.2017.01.041_bib0080","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/0197-0186(94)00123-C","article-title":"Thiamine homeostasis in neuroblastoma cells","volume":"26","author":"Bettendorff","year":"1995","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.neulet.2017.01.041_bib0085","doi-asserted-by":"crossref","first-page":"14379","DOI":"10.1016\/S0021-9258(17)36633-4","article-title":"Mechanism of thiamine transport in neuroblastoma cells. Inhibition of a high affinity carrier by sodium channel activators and dependence of thiamine uptake on membrane potential and intracellular ATP","volume":"269","author":"Bettendorff","year":"1994","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neulet.2017.01.041_bib0090","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0021-9258(19)52451-6","article-title":"Protein measurement with the folin phenol reagent","volume":"193","author":"Lowry","year":"1951","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neulet.2017.01.041_bib0095","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1097\/WNF.0000000000000083","article-title":"Putamina involvement in Wernicke encephalopathy induced by Janus kinase 2 inhibitor","volume":"38","author":"Rodr\u00edguez-Pardo","year":"2015","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.neulet.2017.01.041_bib0100","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1124\/dmd.114.058883","article-title":"The Janus kinase 2 inhibitor fedratinib inhibits thiamine uptake: a putative mechanism for the onset of Wernicke\u2019s encephalopathy","volume":"42","author":"Zhang","year":"2014","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.neulet.2017.01.041_bib0105","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1002\/jcph.218","article-title":"placebo-controlled study of the pharmacokinetics pharmacodynamics, and tolerability of the oral JAK2 inhibitor fedratinib (SAR302503) in healthy volunteers","volume":"54","author":"Zhang","year":"2014","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.neulet.2017.01.041_bib0110","doi-asserted-by":"crossref","first-page":"442","DOI":"10.7196\/SAMJ.9299","article-title":"Encephalopathy after persistent vomiting: three cases of non-alcohol-related Wernicke\u2019s encephalopathy","volume":"105","author":"Antel","year":"2015","journal-title":"S. Afr. Med. J."},{"key":"10.1016\/j.neulet.2017.01.041_bib0115","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1097\/AOG.0000000000000557","article-title":"Iatrogenic Wernicke encephalopathy in a patient with severe hyperemesis gravidarum","volume":"125","author":"Giugale","year":"2015","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.neulet.2017.01.041_bib0120","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1177\/000313481608200401","article-title":"Wernicke encephalopathy after restrictive bariatric surgery","volume":"82","author":"Bohan","year":"2016","journal-title":"Am. Surg."},{"key":"10.1016\/j.neulet.2017.01.041_bib0125","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1054\/clnu.2000.0138","article-title":"Wernicke's syndrome after bariatric surgery","volume":"19","author":"Salas-Salvad\u00f3","year":"2000","journal-title":"Clin. Nutr."},{"key":"10.1016\/j.neulet.2017.01.041_bib0130","first-page":"192","article-title":"Wernicke\u2019s encephalopathy in acquired immune deficiency syndrome (AIDS): a case report","volume":"8","author":"Soffer","year":"1989","journal-title":"Clin. Neuropathol."},{"key":"10.1016\/j.neulet.2017.01.041_bib0135","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/BF00996920","article-title":"Thiamine deficiency and Wernicke\u2019s encephalopathy in AIDS","volume":"6","author":"Butterworth","year":"1991","journal-title":"Metab. Brain Dis."},{"key":"10.1016\/j.neulet.2017.01.041_bib0140","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.neurol.2016.03.002","article-title":"Gayet-Wernicke encephalopathy: a rare and serious complication of gastrointestinal involvement in HIV infection","volume":"172","author":"Ammouri","year":"2016","journal-title":"Rev. Neurol. (Paris)"},{"key":"10.1016\/j.neulet.2017.01.041_bib0145","doi-asserted-by":"crossref","first-page":"C645","DOI":"10.1152\/ajpcell.1999.277.4.C645","article-title":"Transport of thiamine in human intestine: mechanism and regulation in intestinal epithelial cell model Caco-2","volume":"277","author":"Said","year":"1999","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.neulet.2017.01.041_bib0150","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1113\/jphysiol.1982.sp014222","article-title":"Kinetics of thiamine transport across the blood-brain barrier in the rat","volume":"327","author":"Greenwood","year":"1982","journal-title":"J. Physiol."},{"key":"10.1016\/j.neulet.2017.01.041_bib0155","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/0005-2736(84)90463-2","article-title":"Some properties of the thiamine uptake system in isolated rat hepatocytes","volume":"778","author":"Yoshioka","year":"1984","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.neulet.2017.01.041_bib0160","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.neuint.2009.02.020","article-title":"Astrocytes are a major target in thiamine deficiency and Wernicke\u2019s encephalopathy","volume":"55","author":"Hazell","year":"2009","journal-title":"Neurochem. Int."}],"container-title":["Neuroscience Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304394017300617?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304394017300617?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,6,27]],"date-time":"2022-06-27T18:52:35Z","timestamp":1656355955000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304394017300617"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":32,"alternative-id":["S0304394017300617"],"URL":"https:\/\/doi.org\/10.1016\/j.neulet.2017.01.041","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.727229986.793541444","asserted-by":"object"}]},"ISSN":["0304-3940"],"issn-type":[{"value":"0304-3940","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of rats with the JAK-2 inhibitor fedratinib does not lead to experimental Wernicke\u2019s encephalopathy","name":"articletitle","label":"Article Title"},{"value":"Neuroscience Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neulet.2017.01.041","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}